Joseph J. Eron

TL;DR: This Review presents the major points of discussion and consensus views achieved with the goal of informing the conduct of ATIs to maximise the knowledge gained and minimise the risk to participants in clinical HIV research.

TL;DR: Concern about IRIS should not prompt deferral of ART in patients with advanced immunosuppression and non-tuberculous OIs, and the presence of a fungal infection, lower CD4+ T-cell counts and higher HIV RNA levels at baseline, and higher CD4- T- cell counts and lower HIVRNA levels on treatment are associated with IRIS.

TL;DR: The signature patterns identified implicate Env expression levels in selection at viral transmission or in early expansion, and suggest that immune evasion patterns that recur in many individuals during chronic infection when antibodies are present can be selected against when the infection is being established prior to the adaptive immune response.

TL;DR: HIV-associated lymphoma is heterogeneous and changing, with less immunosuppression and greater HIV control at diagnosis, and stable survival and increased mortality for lymphoma occurring on ART call for greater biologic insights to improve outcomes.

TL;DR: Surprisingly, I1Y significantly increased the HLA-A 0201-peptide complex stability at the cell surface and may be an "improved" epitope for use as a CTL-based human immunodeficiency virus vaccine component.